CAPS

Company Overview — What Does Capstone Holding Corp. Do?

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona. Capstone Holding Corp. (CAPS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Matthew E. Lipman and employs approximately 38 people. With a market capitalization of $5M, CAPS is one of the notable companies in the Healthcare sector.

Capstone Holding Corp. (CAPS) Stock Rating — Avoid (April 2026)

As of April 2026, Capstone Holding Corp. receives a Avoid rating with a composite score of 21.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CAPS ranks #4,231 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Capstone Holding Corp. ranks #759 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CAPS Stock Price and 52-Week Range

Capstone Holding Corp. (CAPS) currently trades at $0.52. The stock lost $0.02 (4.0%) in the most recent trading session. The 52-week high for CAPS is $4.18, which means the stock is currently trading -87.6% from its annual peak. The 52-week low is $0.49, putting the stock 6.1% above its annual trough. Recent trading volume was 17K shares, suggesting relatively thin trading activity.

Is CAPS Overvalued or Undervalued? — Valuation Analysis

Capstone Holding Corp. (CAPS) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.19x, versus the sector average of 2.75x. The price-to-sales ratio is 0.15x, compared to 1.66x for the average Healthcare stock.

At current multiples, Capstone Holding Corp. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Capstone Holding Corp. Profitability — ROE, Margins, and Quality Score

Capstone Holding Corp. (CAPS) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -18.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.7% versus the sector average of -33.1%.

On a margin basis, Capstone Holding Corp. reports gross margins of 21.6%, compared to 71.5% for the sector. The operating margin is -8.6% (sector: -66.1%). Net profit margin stands at -14.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CAPS Debt, Balance Sheet, and Financial Health

Capstone Holding Corp. has a debt-to-equity ratio of 43.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.95x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $12M. Cash and equivalents stand at $730,000.

CAPS has a beta of 1.19, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Capstone Holding Corp. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Capstone Holding Corp. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Capstone Holding Corp. reported revenue of $34M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-5M. Gross margin was 21.6%. Operating income came in at $-3M.

In Q3 2025, Capstone Holding Corp. reported revenue of $14M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-2M. Gross margin was 23.8%. Operating income came in at $-768,000.

In Q2 2025, Capstone Holding Corp. reported revenue of $13M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-700,000. Gross margin was 24.3%. Operating income came in at $-260,000.

In Q1 2025, Capstone Holding Corp. reported revenue of $8M and earnings per share (EPS) of $-0.47. Net income for the quarter was $-2M. Gross margin was 16.8%. Operating income came in at $-1M.

Over the past 8 quarters, Capstone Holding Corp. has demonstrated a growth trajectory, with revenue expanding from $0 to $34M. Investors analyzing CAPS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CAPS Dividend Yield and Income Analysis

Capstone Holding Corp. (CAPS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CAPS Momentum and Technical Analysis Profile

Capstone Holding Corp. (CAPS) has a momentum factor score of 13/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.

CAPS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Capstone Holding Corp. (CAPS) ranks #759 out of 838 stocks based on the Blank Capital composite score. This places CAPS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CAPS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CAPS vs S&P 500 (SPY) comparison to assess how Capstone Holding Corp. stacks up against the broader market across all factor dimensions.

CAPS Next Earnings Date

No upcoming earnings date has been announced for Capstone Holding Corp. (CAPS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CAPS? — Investment Thesis Summary

The quantitative profile for Capstone Holding Corp. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. Momentum is weak at 13/100, a headwind for near-term performance. High volatility (stability score 19/100) increases portfolio risk.

In summary, Capstone Holding Corp. (CAPS) earns a Avoid rating with a composite score of 21.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CAPS stock.

Related Resources for CAPS Investors

Explore more research and tools: CAPS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CAPS head-to-head with peers: CAPS vs AZN, CAPS vs SLGL, CAPS vs VMD.